Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 23;104(4):473–479. doi: 10.1136/bjophthalmol-2019-314567

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Comparison of parafoveal capillary density and deviation maps in (top row) healthy control, (middle row) NP-SCR and (bottom row) P-SCR. (Left column) Contrast-stretched full vascular slab OCT-A. (Middle column) Parafoveal capillary density maps with non-capillary blood vessels indicated in white due to the exclusion from density computation. (Right column) Corresponding deviation maps. Parafoveal capillary density below 5% and 1% of the normative database is indicated in yellow and red, respectively. While parafoveal capillary density decreases, total area below 5% and 1% of normal distribution increases with increasing SCR severity. The temporal aspect of the parafovea is to the left in all images. NP-SCR, non-proliferative sickle cell retinopathy; OCT-A, optical coherence tomography angiography; P-SCR, proliferative sickle cell retinopathy.